https://orcid.org/0000-0002-9702-2999
Figures & data
Figure 1. Discretely integrated condition event model. The DICE model conceptualizes “conditions” that reflect aspects of the model or patient attributes that persist, and “events” that reflect points in time when conditions may change. Times to events are initially determined at the start of the model. These times are periodically revised during Update, Valuate, Response Assessment, and Last Response Assessment events, which are part of the scheduling process represented by the clock, and when other events occur, as indicated by arrowheads. Abbreviations. AP, antipsychotic; DICE, discretely integrated condition event; Rx, prescription; TD, tardive dyskinesia.
Table 1. Clinical inputs: dosing, probability of response, antipsychotic treatment discontinuation, psychiatric condition relapses, and mortality.
Table 2. Tardive dyskinesia treatment cost inputs.
Table 3. Lifetime health and cost outcomes of tardive dyskinesia treatment with valbenazine and deutetrabenazine.
Table 4. Lifetime discounted costs (2017 US $) of tardive dyskinesia treatment with valbenazine and deutetrabenazine.
Figure 2. Tornado plots for deterministic sensitivity analysis of valbenazine compared with deutetrabenazine. (a) Incremental Lifetime Costs. (b) Incremental QALYs. Analysis based on response criterion of ≥50% improvement in AIMS total score in patients with any psychiatric diagnosis at baseline. Incremental lifetime costs are relative to the base case difference between valbenazine and deutetrabenazine of $1,176. Incremental QALYs are relative to the base case difference between valbenazine and deutetrabenazine of 0.118. Abbreviations. AIMS, Abnormal Involuntary Movement Scale; DTBZ, deutetrabenazine; MDD, major depressive disorder; ITC, indirect treatment comparison; QALY, quality-adjusted life year; TD, tardive dyskinesia; VBZ, valbenazine.
Figure 3. Cost-effectiveness plane for probabilistic sensitivity analysis of valbenazine compared with deutetrabenazine. Analysis based on 100 model simulations using response criterion of ≥50% improvement in AIMS total score in patients with any psychiatric diagnosis at baseline. Abbreviations. AIMS, Abnormal Involuntary Movement Scale; PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life year.
Figure 4. Cost-effectiveness acceptability curves for valbenazine and deutetrabenazine. Abbreviations. DTBZ, deutetrabenazine; QALY, quality-adjusted life year; VBZ, valbenazine.
